CN113209185B - 一种广谱抗病毒中药挥发油制剂及其应用 - Google Patents
一种广谱抗病毒中药挥发油制剂及其应用 Download PDFInfo
- Publication number
- CN113209185B CN113209185B CN202110539335.0A CN202110539335A CN113209185B CN 113209185 B CN113209185 B CN 113209185B CN 202110539335 A CN202110539335 A CN 202110539335A CN 113209185 B CN113209185 B CN 113209185B
- Authority
- CN
- China
- Prior art keywords
- volatile oil
- parts
- leaf
- raw materials
- leaves
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000341 volatile oil Substances 0.000 title claims abstract description 193
- 239000003814 drug Substances 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 29
- 230000000840 anti-viral effect Effects 0.000 title claims abstract description 20
- 235000005979 Citrus limon Nutrition 0.000 claims abstract description 27
- 244000131522 Citrus pyriformis Species 0.000 claims abstract description 27
- 235000007303 Thymus vulgaris Nutrition 0.000 claims abstract description 20
- 239000001585 thymus vulgaris Substances 0.000 claims abstract description 20
- 235000009024 Ceanothus sanguineus Nutrition 0.000 claims abstract description 19
- 235000007519 Chimonanthus praecox Nutrition 0.000 claims abstract description 19
- 240000000691 Houttuynia cordata Species 0.000 claims abstract description 19
- 240000003553 Leptospermum scoparium Species 0.000 claims abstract description 19
- 235000015459 Lycium barbarum Nutrition 0.000 claims abstract description 19
- 235000015987 Origanum dictamnus Nutrition 0.000 claims abstract description 19
- 235000004383 Origanum vulgare subsp. vulgare Nutrition 0.000 claims abstract description 19
- 235000013719 Houttuynia cordata Nutrition 0.000 claims abstract description 18
- 240000005125 Myrtus communis Species 0.000 claims abstract description 18
- 235000013418 Myrtus communis Nutrition 0.000 claims abstract description 18
- 241000700605 Viruses Species 0.000 claims abstract description 18
- 244000004281 Eucalyptus maculata Species 0.000 claims abstract description 17
- 241000544656 Cedrus atlantica Species 0.000 claims abstract description 16
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims abstract description 11
- 241000711467 Human coronavirus 229E Species 0.000 claims abstract description 10
- 240000000278 Syzygium polyanthum Species 0.000 claims abstract description 10
- 235000008089 Syzygium polyanthum Nutrition 0.000 claims abstract description 10
- 240000002547 Rosa roxburghii Species 0.000 claims abstract description 6
- 235000000640 Rosa roxburghii Nutrition 0.000 claims abstract description 6
- 240000002657 Thymus vulgaris Species 0.000 claims abstract description 6
- 240000001359 Origanum dictamnus Species 0.000 claims abstract 5
- 239000002994 raw material Substances 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 18
- 238000000605 extraction Methods 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 238000009210 therapy by ultrasound Methods 0.000 claims description 11
- 238000004821 distillation Methods 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 9
- 239000002245 particle Substances 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 238000001256 steam distillation Methods 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- 244000025254 Cannabis sativa Species 0.000 claims description 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 6
- 238000004140 cleaning Methods 0.000 claims description 6
- 238000003815 supercritical carbon dioxide extraction Methods 0.000 claims description 6
- 238000005292 vacuum distillation Methods 0.000 claims description 5
- 240000006066 Rosa rugosa Species 0.000 claims description 4
- 235000000659 Rosa rugosa Nutrition 0.000 claims description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 3
- 239000001569 carbon dioxide Substances 0.000 claims description 3
- 238000009833 condensation Methods 0.000 claims description 3
- 230000005494 condensation Effects 0.000 claims description 3
- 238000003892 spreading Methods 0.000 claims description 3
- 230000007480 spreading Effects 0.000 claims description 3
- 244000147568 Laurus nobilis Species 0.000 claims description 2
- 235000017858 Laurus nobilis Nutrition 0.000 claims description 2
- 235000005212 Terminalia tomentosa Nutrition 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims 1
- 210000004072 lung Anatomy 0.000 abstract description 31
- 206010035664 Pneumonia Diseases 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 10
- 238000012360 testing method Methods 0.000 abstract description 6
- 230000034994 death Effects 0.000 abstract description 2
- 230000002888 effect on disease Effects 0.000 abstract description 2
- 230000002035 prolonged effect Effects 0.000 abstract description 2
- 230000002685 pulmonary effect Effects 0.000 abstract description 2
- 230000004083 survival effect Effects 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 240000001825 Chimonanthus praecox Species 0.000 description 15
- 241000246358 Thymus Species 0.000 description 14
- 230000000052 comparative effect Effects 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 8
- GRWFGVWFFZKLTI-UHFFFAOYSA-N α-pinene Chemical compound CC1=CCC2C(C)(C)C1C2 GRWFGVWFFZKLTI-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 206010057190 Respiratory tract infections Diseases 0.000 description 6
- UAHWPYUMFXYFJY-UHFFFAOYSA-N beta-myrcene Chemical compound CC(C)=CCCC(=C)C=C UAHWPYUMFXYFJY-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- HFPZCAJZSCWRBC-UHFFFAOYSA-N p-cymene Chemical compound CC(C)C1=CC=C(C)C=C1 HFPZCAJZSCWRBC-UHFFFAOYSA-N 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 229960005233 cineole Drugs 0.000 description 5
- 239000007923 nasal drop Substances 0.000 description 5
- 229940100662 nasal drops Drugs 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- GRWFGVWFFZKLTI-IUCAKERBSA-N 1S,5S-(-)-alpha-Pinene Natural products CC1=CC[C@@H]2C(C)(C)[C@H]1C2 GRWFGVWFFZKLTI-IUCAKERBSA-N 0.000 description 4
- WRYLYDPHFGVWKC-UHFFFAOYSA-N 4-terpineol Chemical compound CC(C)C1(O)CCC(C)=CC1 WRYLYDPHFGVWKC-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 4
- 102000006992 Interferon-alpha Human genes 0.000 description 4
- 108010047761 Interferon-alpha Proteins 0.000 description 4
- 238000000692 Student's t-test Methods 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- MVNCAPSFBDBCGF-UHFFFAOYSA-N alpha-pinene Natural products CC1=CCC23C1CC2C3(C)C MVNCAPSFBDBCGF-UHFFFAOYSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000001543 one-way ANOVA Methods 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 238000012353 t test Methods 0.000 description 4
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 3
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 3
- 240000006891 Artemisia vulgaris Species 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 241000723346 Cinnamomum camphora Species 0.000 description 3
- 241000711573 Coronaviridae Species 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 241000725643 Respiratory syncytial virus Species 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 229930008380 camphor Natural products 0.000 description 3
- 229960000846 camphor Drugs 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 3
- XMGQYMWWDOXHJM-JTQLQIEISA-N (+)-α-limonene Chemical compound CC(=C)[C@@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-JTQLQIEISA-N 0.000 description 2
- WTARULDDTDQWMU-RKDXNWHRSA-N (+)-β-pinene Chemical compound C1[C@H]2C(C)(C)[C@@H]1CCC2=C WTARULDDTDQWMU-RKDXNWHRSA-N 0.000 description 2
- WTARULDDTDQWMU-IUCAKERBSA-N (-)-Nopinene Natural products C1[C@@H]2C(C)(C)[C@H]1CCC2=C WTARULDDTDQWMU-IUCAKERBSA-N 0.000 description 2
- WUOACPNHFRMFPN-SECBINFHSA-N (S)-(-)-alpha-terpineol Chemical compound CC1=CC[C@@H](C(C)(C)O)CC1 WUOACPNHFRMFPN-SECBINFHSA-N 0.000 description 2
- WRYLYDPHFGVWKC-SNVBAGLBSA-N 4-Terpineol Natural products CC(C)[C@]1(O)CCC(C)=CC1 WRYLYDPHFGVWKC-SNVBAGLBSA-N 0.000 description 2
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 description 2
- 235000003097 Artemisia absinthium Nutrition 0.000 description 2
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 description 2
- DTGKSKDOIYIVQL-UHFFFAOYSA-N Borneol Chemical compound C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241001500351 Influenzavirus A Species 0.000 description 2
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 2
- 241000218195 Lauraceae Species 0.000 description 2
- 101000648740 Mus musculus Tumor necrosis factor Proteins 0.000 description 2
- 241000219926 Myrtaceae Species 0.000 description 2
- ZYEMGPIYFIJGTP-UHFFFAOYSA-N O-methyleugenol Chemical compound COC1=CC=C(CC=C)C=C1OC ZYEMGPIYFIJGTP-UHFFFAOYSA-N 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- WTARULDDTDQWMU-UHFFFAOYSA-N Pseudopinene Natural products C1C2C(C)(C)C1CCC2=C WTARULDDTDQWMU-UHFFFAOYSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 241001093501 Rutaceae Species 0.000 description 2
- MOYAFQVGZZPNRA-UHFFFAOYSA-N Terpinolene Chemical compound CC(C)=C1CCC(C)=CC1 MOYAFQVGZZPNRA-UHFFFAOYSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 2
- 241001251949 Xanthium sibiricum Species 0.000 description 2
- KGEKLUUHTZCSIP-HOSYDEDBSA-N [(1s,4s,6r)-1,7,7-trimethyl-6-bicyclo[2.2.1]heptanyl] acetate Chemical compound C1C[C@]2(C)[C@H](OC(=O)C)C[C@H]1C2(C)C KGEKLUUHTZCSIP-HOSYDEDBSA-N 0.000 description 2
- XCPQUQHBVVXMRQ-UHFFFAOYSA-N alpha-Fenchene Natural products C1CC2C(=C)CC1C2(C)C XCPQUQHBVVXMRQ-UHFFFAOYSA-N 0.000 description 2
- OVKDFILSBMEKLT-UHFFFAOYSA-N alpha-Terpineol Natural products CC(=C)C1(O)CCC(C)=CC1 OVKDFILSBMEKLT-UHFFFAOYSA-N 0.000 description 2
- 229940088601 alpha-terpineol Drugs 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 239000001138 artemisia absinthium Substances 0.000 description 2
- 229930006722 beta-pinene Natural products 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- ULDHMXUKGWMISQ-UHFFFAOYSA-N carvone Chemical compound CC(=C)C1CC=C(C)C(=O)C1 ULDHMXUKGWMISQ-UHFFFAOYSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000012847 fine chemical Substances 0.000 description 2
- LCWMKIHBLJLORW-UHFFFAOYSA-N gamma-carene Natural products C1CC(=C)CC2C(C)(C)C21 LCWMKIHBLJLORW-UHFFFAOYSA-N 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 238000010832 independent-sample T-test Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- -1 patches Substances 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- YKFLAYDHMOASIY-UHFFFAOYSA-N γ-terpinene Chemical compound CC(C)C1=CCC(C)=CC1 YKFLAYDHMOASIY-UHFFFAOYSA-N 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- NZGWDASTMWDZIW-MRVPVSSYSA-N (+)-pulegone Chemical compound C[C@@H]1CCC(=C(C)C)C(=O)C1 NZGWDASTMWDZIW-MRVPVSSYSA-N 0.000 description 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- 239000001716 (4-methyl-1-propan-2-yl-1-cyclohex-2-enyl) acetate Substances 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- YSTPAHQEHQSRJD-UHFFFAOYSA-N 3-Carvomenthenone Chemical compound CC(C)C1CCC(C)=CC1=O YSTPAHQEHQSRJD-UHFFFAOYSA-N 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- 206010006448 Bronchiolitis Diseases 0.000 description 1
- 239000005973 Carvone Substances 0.000 description 1
- 241000218645 Cedrus Species 0.000 description 1
- 241000723440 Chimonanthus Species 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 208000001528 Coronaviridae Infections Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- PSMFFFUWSMZAPB-UHFFFAOYSA-N Eukalyptol Natural products C1CC2CCC1(C)COCC2(C)C PSMFFFUWSMZAPB-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 235000013717 Houttuynia Nutrition 0.000 description 1
- 244000309467 Human Coronavirus Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000218641 Pinaceae Species 0.000 description 1
- NZGWDASTMWDZIW-UHFFFAOYSA-N Pulegone Natural products CC1CCC(=C(C)C)C(=O)C1 NZGWDASTMWDZIW-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 241001527977 Rhamnella Species 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 241000534017 Saururus chinensis Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- IGODOXYLBBXFDW-UHFFFAOYSA-N alpha-Terpinyl acetate Chemical compound CC(=O)OC(C)(C)C1CCC(C)=CC1 IGODOXYLBBXFDW-UHFFFAOYSA-N 0.000 description 1
- VYBREYKSZAROCT-UHFFFAOYSA-N alpha-myrcene Natural products CC(=C)CCCC(=C)C=C VYBREYKSZAROCT-UHFFFAOYSA-N 0.000 description 1
- USMNOWBWPHYOEA-UHFFFAOYSA-N alpha-thujone Natural products CC1C(=O)CC2(C(C)C)C1C2 USMNOWBWPHYOEA-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- 229940115397 bornyl acetate Drugs 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- IRAQOCYXUMOFCW-CXTNEJHOSA-N cedrene Chemical compound C1[C@]23[C@H](C)CC[C@H]3C(C)(C)[C@H]1C(C)=CC2 IRAQOCYXUMOFCW-CXTNEJHOSA-N 0.000 description 1
- SVURIXNDRWRAFU-OGMFBOKVSA-N cedrol Chemical compound C1[C@]23[C@H](C)CC[C@H]3C(C)(C)[C@@H]1[C@@](O)(C)CC2 SVURIXNDRWRAFU-OGMFBOKVSA-N 0.000 description 1
- 229940026455 cedrol Drugs 0.000 description 1
- PCROEXHGMUJCDB-UHFFFAOYSA-N cedrol Natural products CC1CCC2C(C)(C)C3CC(C)(O)CC12C3 PCROEXHGMUJCDB-UHFFFAOYSA-N 0.000 description 1
- KMPWYEUPVWOPIM-UHFFFAOYSA-N cinchonidine Natural products C1=CC=C2C(C(C3N4CCC(C(C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-UHFFFAOYSA-N 0.000 description 1
- RFFOTVCVTJUTAD-UHFFFAOYSA-N cineole Natural products C1CC2(C)CCC1(C(C)C)O2 RFFOTVCVTJUTAD-UHFFFAOYSA-N 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- YKNMBTZOEVIJCM-UHFFFAOYSA-N dec-2-ene Chemical compound CCCCCCCC=CC YKNMBTZOEVIJCM-UHFFFAOYSA-N 0.000 description 1
- IRAQOCYXUMOFCW-UHFFFAOYSA-N di-epi-alpha-cedrene Natural products C1C23C(C)CCC3C(C)(C)C1C(C)=CC2 IRAQOCYXUMOFCW-UHFFFAOYSA-N 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000000531 effect on virus Effects 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001309 inhibitory effect on influenza Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- SVURIXNDRWRAFU-UHFFFAOYSA-N juniperanol Natural products C1C23C(C)CCC3C(C)(C)C1C(O)(C)CC2 SVURIXNDRWRAFU-UHFFFAOYSA-N 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 208000030500 lower respiratory tract disease Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229930003658 monoterpene Natural products 0.000 description 1
- 150000002773 monoterpene derivatives Chemical class 0.000 description 1
- 235000002577 monoterpenes Nutrition 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 description 1
- 235000007743 myricetin Nutrition 0.000 description 1
- 229940116852 myricetin Drugs 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 229930007459 p-menth-8-en-3-one Natural products 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 229930006968 piperitone Natural products 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/78—Saururaceae (Lizard's-tail family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种广谱抗病毒中药挥发油制剂及其应用。本发明茶树挥发油、山腊梅挥发油、百里香挥发油、月桂叶挥发油、尤加利挥发油、柠檬挥发油、鱼腥草挥发油、香桃木挥发油、罗纹莎叶挥发油、大西洋雪松挥发油、艾叶挥发油,这十一种挥发油中的有效成分各不相同,各组分协同作用,对不同的病毒引起的疾病有着不错的治疗作用,可降低肺指数,减少死亡率,延长生存时间;经试验证明,本发明提供的中药挥发油制剂对副流感病毒(仙台株)所致小鼠肺炎模型和人冠状病毒229E所致小鼠肺炎模型的肺指数均有明显降低作用。
Description
技术领域
本发明涉及中药技术领域,特别涉及一种广谱抗病毒中药挥发油制剂及其应用。
背景技术
人类副流感病毒(HPIVs)常常引起儿童下呼吸道感染的一种病毒,其致病性仅次于呼吸道合胞病毒 (RSV)。与RSV一样,人类副流感病毒可以造成反复发作的上呼吸道感染(如感冒和喉咙痛),它也能造成严重的反复感染的下呼吸道疾病(如肺炎,支气管炎和细支气管炎),特别是在老年人中和有免疫缺陷人群中。
人冠状病毒229E属α群正链RNA病毒冠状病毒,主要引起人类呼吸道感染。人冠状病毒感染呈全球性分布,人群普遍易感,多项血清学研究结果表明,几乎100%的儿童在幼年早期均感染过HcoV-229E和NL63。HCoV-229E主要感染呼吸道和肠黏膜表面。感染呼吸道主要引起轻度呼吸道感染症状,典型表现为流涕、咽喉肿痛、咳嗽、头痛、发热等普通感冒症状,少部分病例因上呼吸道感染住院。研究表明,引起呼吸道感染的病例中,出现呼吸困难症状66.6%是由HcoV-229E引起的。
目前西药治疗由上述病毒引起的疾病只能临时控制病情,服用太多消炎药、抗生素或磺胺类药会导致人体阴阳失去平衡、免疫功能低下,抵抗力减退,致使病情反复难愈。而我国传统中药具有副作用小、调理功能出众、对抗病毒具有较好疗效等特点。
发明内容
本发明的目的在于提供一种广谱抗病毒中药挥发油制剂及其应用,以解决上述技术问题。
为了实现上述目的,本发明的技术方案为:
第一方面,本发明提供的一种广谱抗病毒中药挥发油制剂,按重量份数计,包括如下原料:茶树挥发油10~20份、山腊梅挥发油10~20份、百里香挥发油10~20份、月桂叶挥发油5~10份、尤加利挥发油5~10份、柠檬挥发油5~10份、鱼腥草挥发油5~10份、香桃木挥发油5~10份、罗纹莎叶挥发油5~10份、大西洋雪松挥发油5~10份、艾叶挥发油5~10份。
优选的,所述广谱抗病毒中药挥发油制剂,按重量份数计,包括如下原料:茶树挥发油15份、山腊梅挥发油15份、百里香挥发油15份、月桂叶挥发油6份、尤加利挥发油6份、柠檬挥发油6份、鱼腥草挥发油7份、香桃木挥发油7.5份、罗纹莎叶挥发油7.5份、大西洋雪松挥发油7.5份、艾叶挥发油7.5份。
优选的,所述茶树挥发油、山腊梅挥发油、月桂叶挥发油、尤加利挥发油、香桃木挥发油、罗纹莎叶挥发油、大西洋雪松挥发油和艾叶挥发油分别以茶树叶片、山腊梅叶片、月桂叶片、尤加利叶片、香桃木叶片、罗纹莎叶片、大西洋雪松针叶和艾叶为原料,分别通过下述方法制得:将对应的叶片原料洗净后平铺在烘房中,放置15~25小时,蒸汽杀青后,气流干燥处理至叶片的水分含量不高于20%,粉碎得到粉末,在0~10℃下冷冻4~10小时,再恢复至25~35℃,再加入0.5~2倍重量的水中,在30~50℃下超声处理2~8小时,然后抽真空蒸馏1~3次,收集蒸馏液进行超临界二氧化碳萃取即可。
进一步优选的,所述蒸汽杀青的条件为:温度为120~130℃,时间为20~40s。
进一步优选的,所述气流干燥的条件为:气流速率2~5m3/h。
进一步优选的,所述抽真空蒸馏的条件为:真空度0.3~0.8Pa,蒸馏温度40~50℃,冷凝温度3~5℃。
进一步优选的,所述超临界二氧化碳萃取的条件为:萃取压力为15~18MPa,萃取时间为60~90min,萃取温度为45~55℃,二氧化碳的流速为20~40L/h。
优选的,所述百里香挥发油和鱼腥草挥发油分别以百里香全草和鱼腥草全草为原料,分别通过下述方法制得:将新鲜的全草原料洗净后干燥至水分不高于15%,粉碎后加入5~10倍重量的水中,在30~50℃下超声处理1~2小时,然后水蒸气蒸馏提取1~3小时,收集蒸馏液,将蒸馏液进行减压精馏,分离出挥发油。
进一步优选的,所述减压蒸馏的条件为:温度为50~80℃,真空度为50~90Pa,搅拌速率为100~300r/min。
优选的,所述柠檬挥发油为采用下述方法制得:将新鲜的的柠檬果皮粉碎得到柠檬皮碎粒,将柠檬片碎粒加入1~3倍重量的水中,在30~50℃下超声处理30~60min,然后水蒸气蒸馏提取2~4小时,收集蒸馏液,,将蒸馏液进行减压精馏,分离出柠檬挥发油。
进一步优选的,所述减压蒸馏的条件为:温度为50~70℃,真空度为50~90Pa,搅拌速率为200~500r/min。
优选的,所述广谱抗病毒中药挥发油制剂是将茶树挥发油、山腊梅挥发油、百里香挥发油、月桂叶挥发油、尤加利挥发油、柠檬挥发油、鱼腥草挥发油、香桃木挥发油、罗纹莎叶挥发油、大西洋雪松挥发油、艾叶挥发油混合均匀而成的。
第二方面,本发明提供的一种如第一方面所述的广谱抗病毒中药挥发油制剂在制备抗病毒药物中的应用。
优选的,所述抗病毒药物是由药学可接受的载体与所述广谱抗病毒中药挥发油制剂制备而成的剂型。
进一步优选的,所述药学上可接受的载体选自赋形剂、黏合剂、填充剂、润滑剂、抗氧剂、防腐剂和增稠剂中的一种或多种。
进一步优选的,所述剂型选自滴鼻剂、凝胶剂、膏剂、贴剂、搽剂、酊剂、洗剂、涂膜剂和贴膏剂中的任意一种。
优选的,所述抗病毒药物为抗人类副流感病毒药物、抗人冠状病毒药物中的任意一种。
与现有技术相比,本发明的有益效果在于:
本发明茶树挥发油、山腊梅挥发油、百里香挥发油、月桂叶挥发油、尤加利挥发油、柠檬挥发油、鱼腥草挥发油、香桃木挥发油、罗纹莎叶挥发油、大西洋雪松挥发油、艾叶挥发油,这十一种挥发油中的有效成分各不相同,各组分协同作用,对不同的病毒引起的疾病有着不错的治疗作用,可降低肺指数,减少死亡率,延长生存时间;经试验证明,本发明提供的中药挥发油制剂对副流感病毒(仙台株)所致小鼠肺炎模型和人冠状病毒229E所致小鼠肺炎模型的肺指数均有明显降低作用。
本发明包含的中药成分的作用如下:
山腊梅:腊梅科植物,其主要成分包括α-蒎烯、β-莰烯、蒎烯、1, 8-桉叶素、樟脑、龙脑、异龙脑,山腊梅挥发油中含有脱氢香橙烯,其次是 (-) -匙叶桉油烯醇, α-杜松醇,(+) -匙叶桉油烯醇,山腊梅对流感病毒有着很好的抑制作用,广泛应用于感冒等疾病,其挥发油也有着镇痛、止咳、平喘的作用;
茶树:山茶科植物,其挥发油主要成分包括对伞花烃、松油烯-4-醇、萜品油烯、1,8-桉叶素、α-pine烯、γ-萜品烯等化合物,有着不错的抗炎、抗菌、抗病毒作用;
月桂叶:樟科植物,其挥发油主要成分包括1,8-桉油醇、乙酸松油脂、丁香酚甲醚、去氢夙毛菊内酯、α-松油醇等,有着抗病毒活性,也对各种细菌有着很好的抑制作用;
尤加利:也叫桉树,桃金娘科植物,主要含有1,8-桉叶醇、桉叶油素、萜烯、异戊叶油、葛缕酮、胡薄荷酮、胡椒酮等物质,有着不错的抗炎,抗肿瘤,抗病毒作用;
柠檬:芸香科植物,其挥发油主要含有对甲苯、柠檬烯、芳香醇,一有研究表明,其对新型冠状病毒有着很好的抑制作用;
鱼腥草:三百草科植物,其挥发油主要含有β-蒎烯、D-柠檬烯、甲基正壬酮、ɑ-蒎烯、乙酸龙脑酯、β-月桂烯和4-萜品醇等化合物,有着不错的抗炎、抗病毒、抗菌等作用;
香桃木:桃金娘科植物,主要含有槲皮素和杨梅素两种化合物,主要有着抗氧化、抗炎、抗病毒作用;
罗纹莎叶:樟科植物,以抗病毒作用闻名,有着很好的挥发性,其挥发油主要含有桉叶油醇、樟脑、香树烯、对伞花烃、β-蒎烯等物质,有着很好的抑菌作用;
百里香:唇形科植物,百里香挥发油主要含有对异丙基甲苯、百里酚、芳樟醇、α-蒎烯、α-松油醇、β-月桂烯等化合物,有着很好的抗病毒作用;
大西洋雪松:松科植物,其挥发油主要含有雪松烯、雪松醇、大西洋酮等,有着很好的安抚情绪的作用,抗菌活性强,有助于提高免疫系统;
艾叶:菊科植物,其挥发油主要含有单萜类、倍半萜类、黄酮类和酚酸类等物质,包括桉油精、樟脑和龙脑,市面上常用于抗菌、抗炎。
具体实施方式
下面对本发明的具体实施方式作进一步说明。在此需要说明的是,对于这些实施方式的说明用于帮助理解本发明,但并不构成对本发明的限定。此外,下面所描述的本发明各个实施方式中所涉及的技术特征只要彼此之间未构成冲突就可以相互组合。
在以下实施例和对比例中,茶树挥发油、山腊梅挥发油、月桂叶挥发油、尤加利挥发油、香桃木挥发油、罗纹莎叶挥发油、大西洋雪松挥发油和艾叶挥发油分别以茶树叶片、山腊梅叶片、月桂叶片、尤加利叶片、香桃木叶片、罗纹莎叶片、大西洋雪松针叶和艾叶为原料,分别通过下述方法制得:将对应的叶片原料洗净后平铺在烘房中,放置20小时,以125℃的蒸汽杀青30s,气流干燥处理至叶片的水分含量为12~15%,粉碎得到100目的粉末,在5℃下冷藏6小时,再恢复至30℃,再加入1倍重量的水中,在45℃下超声处理4小时,然后在真空度0.6Pa、蒸馏温度45℃、冷凝温度4℃的条件下抽真空蒸馏2次,收集蒸馏液进行超临界二氧化碳萃取即可,其中,超临界二氧化碳萃取的条件为:萃取压力为16MPa,萃取时间为70min,萃取温度为50℃,二氧化碳的流速为30L/h。
在以下实施例和对比例中,百里香挥发油和鱼腥草挥发油的制备方法,包括如下步骤:百里香挥发油和鱼腥草挥发油分别以百里香全草和鱼腥草全草为原料,将新鲜的全草原料洗净后干燥至水分10~15%,粉碎后加入6倍重量的水中,在45℃下超声处理1.5小时,然后将超声处理后的料液转入蒸馏设备中,水蒸气蒸馏提取2小时,收集蒸馏液,将蒸馏液进行减压精馏,分离出挥发油,其中,所述减压蒸馏的条件为:温度为70℃,真空度为70Pa,搅拌速率为200r/min。
在以下实施例和对比例中,柠檬挥发油的制备方法,包括如下步骤:将新鲜的的柠檬果皮粉碎得到柠檬皮碎粒,将柠檬片碎粒加入相同重量的水中,在40℃下超声处理45min,然后水蒸气蒸馏提取3小时,收集蒸馏液,将蒸馏液进行减压精馏,其中,所述减压蒸馏的条件为:温度为60℃,真空度为60Pa,搅拌速率为400r/min,分离出柠檬挥发油。
实施例1~5
称取如下表1所示重量份数的原料,将茶树挥发油、山腊梅挥发油、百里香挥发油、月桂叶挥发油、尤加利挥发油、柠檬挥发油、鱼腥草挥发油、香桃木挥发油、罗纹莎叶挥发油、大西洋雪松挥发油、艾叶挥发油混合均匀即可。
表1 各原料的配比
原料/(单位:重量份) | 实施例1 | 实施例2 | 实施例3 | 实施例4 | 实施例5 |
茶树挥发油 | 15 | 10 | 18 | 12 | 20 |
山腊梅挥发油 | 15 | 20 | 18 | 12 | 10 |
百里香挥发油 | 15 | 20 | 15 | 12 | 10 |
月桂叶挥发油 | 6 | 5 | 6 | 8 | 10 |
尤加利挥发油 | 6 | 5 | 6 | 8 | 10 |
柠檬挥发油 | 6 | 10 | 6 | 8 | 5 |
鱼腥草挥发油 | 7 | 10 | 6 | 8 | 5 |
香桃木挥发油 | 7.5 | 5 | 6 | 8 | 5 |
罗纹莎叶挥发油 | 7.5 | 5 | 6 | 8 | 5 |
大西洋雪松挥发油 | 7.5 | 5 | 7 | 8 | 10 |
艾叶挥发油 | 7.5 | 5 | 6 | 8 | 10 |
(一)中药挥发油制剂对副流感病毒(仙台株)致小鼠肺炎模型的治疗作用
1.实验材料
1.1 动物及分组
选用SPF级ICR小鼠50只,雌雄各半,9-12周龄,体重13-15g,购于江西中医药大学实验动物科技中心[合格证号:SCXK(赣)2018-0003]。清洁级动物房饲养,统一光照时间为06:00~18:00,恒温,恒湿,自由饮水,饲固体饲料。适应性喂养3 d后用于实验。按随机数字表法分为以下5组,每组10只:
正常对照组、
模型对照组、
中药挥发油制剂大、中、小三个剂量组
1.2 实验药物
由实施例1的方法制备中药挥发油制剂。
1.3 主要试剂
Trizol Reagent购于Ambion by life technology(批号:257403)、InfluenzaVirus A Real Time RT-PCR Kit购于上海之江生物科技股份有限公司(批号:NOP20200101)、乙醚购于上海市鸿盛精细化工有限公司(批号:20181009)、小鼠α干扰素(IFN-α)酶联免疫分析购于上海酶联生物科技有限公司(批号:NO03/2019)、小鼠MDA酶联免疫分析购于上海酶联生物科技有限公司(批号:NO07/2020)、小鼠肿瘤坏死因子α(TNF-α)酶联免疫分析购于美国bio-techne(批号:NO546999)。
1.4主要仪器
A2型生物安全柜(型号:Thermo MSC1.8),A2型生物安全柜(型号:Thermo MSC1.2)均购于美国Thermo公司,A2型生物安全柜(型号:Nuaire NU-425-400E)购于美国Nuaire,电子天平(型号:YP1002 MAX100g)购于上海越平科学仪器有限公司,电子分析天平(型号:Ltem-AR 1140 MAX110g)购于Ohaus Corp. Brock. WJ. USA,电子天平(型号:AL204)购于梅特勒-托利多仪器(上海)有限公司,Real-Time PCR Instrument(型号:QuantStudio 5)购于Applied biosystems,八连排管迷你离心机(型号:LX-300)购于Kylin-Bell LabInstruments,迷你涡旋振荡器(型号:QL-901)购于海门市其林贝尔仪器制造有限公司,低温高速离心机(型号Eppendorf-5810R)购于eppendorf,电子分析天平(型号:AR1140)购于Ohaus Corp.Brock.NJ.USA,多功能酶标仪(型号Enspire)购于PerkinElmer,超声细胞破碎仪(型号:SONIC RUPTOR 400)购于MONI homogenizer company,震荡裂解仪(型号:FastprepTM-24)购于MP Biomedicals,IVC小鼠饲养笼(型号:ZJ-4)购于苏州市冯氏实验动物设备有限公司。
2.实验方法
2.1除正常对照组外,将小鼠用乙醚轻度麻醉,以15个LD50副流感病毒(仙台株)滴鼻感染,每只45μl。感染当天开始给药,大、中、小剂量组每次以滴鼻方式给药,给药剂量如表2所示,每天1次,连续4天,正常对照组和模型对照组在同等条件下蒸馏水滴鼻。第5天称重后解剖。取肺称肺重,计算肺指数及肺指数抑制率。结果采用组间比较t检验进行统计学处理。计算公式如下:
肺指数(%)=[肺湿重(g) / 体重(g)] ×100%;
肺指数抑制率(%)=[模型对照组肺重(g)-给药组肺重(g)]/[模型对照组肺重(g)-正常对照组肺重(g)]×100%。
2.2统计方法
采用SPSS 22.0软件进行统计,组间比较采用对照t检验和单因素方差分析,以`x±s表示,采用独立样本t检验或单因素方差分析(ANOVA),然后进行Dunnet检验用于多重比较组间差异,以P<0.05表示统计结果差异具有统计学意义。
3实验结果
表2 对副流感病毒(仙台株)感染小鼠肺炎模型的治疗作用
注:与正常组比较## P<0.01;与模型对照组比较,*P<0.05,** P<0.01
4.讨论
采用副流感病毒(仙台株)感染小鼠后,小鼠肺指数明显增高,与正常对照组比较有明显性差异(P<0.01);感染当天开始给予中药挥发油制剂治疗4天后,中药挥发油制剂大、中剂量组肺指数明显降低,与模型对照组比较有明显性差异(P<0.05,P<0.01),肺指数抑制率分别为45.75%、37.01%。
(二)中药挥发油制剂对人冠状病毒229E致小鼠肺炎模型的治疗作用
1.实验材料
1.1 动物及分组
选用SPF级ICR小鼠50只,雌雄各半,9-12周龄,体重13-15g,购于江西中医药大学实验动物科技中心[合格证号:SCXK(赣)2018-0003]。清洁级动物房饲养,统一光照时间为06:00~18:00,恒温,恒湿,自由饮水,饲固体饲料。适应性喂养3 d后用于实验。按随机数字表法分为以下5组,每组10只:
正常对照组
模型对照组
中药挥发油制剂大、中、小三个剂量组
1.2 实验药物
由实施例1的方法制备中药挥发油制剂。
1.3 主要试剂
Trizol Reagent购于Ambion by life technology(批号:257403)、InfluenzaVirus A Real Time RT-PCR Kit购于上海之江生物科技股份有限公司(批号:NOP20200101)、乙醚购于上海市鸿盛精细化工有限公司(批号:20181009)、小鼠α干扰素(IFN-α)酶联免疫分析购于上海酶联生物科技有限公司(批号:NO03/2019)、小鼠MDA酶联免疫分析购于上海酶联生物科技有限公司(批号:NO07/2020)、小鼠肿瘤坏死因子α(TNF-α)酶联免疫分析购于美国bio-techne(批号:NO546999)。
1.4主要仪器
A2型生物安全柜(型号:Thermo MSC1.8),A2型生物安全柜(型号:Thermo MSC1.2)均购于美国Thermo公司,A2型生物安全柜(型号:Nuaire NU-425-400E)购于美国Nuaire,电子天平(型号:YP1002 MAX100g)购于上海越平科学仪器有限公司,电子分析天平(型号:Ltem-AR 1140 MAX110g)购于Ohaus Corp. Brock. WJ. USA,电子天平(型号:AL204)购于梅特勒-托利多仪器(上海)有限公司,Real-Time PCR Instrument(型号:QuantStudio 5)购于Applied biosystems,八连排管迷你离心机(型号:LX-300)购于Kylin-Bell LabInstruments,迷你涡旋振荡器(型号:QL-901)购于海门市其林贝尔仪器制造有限公司,低温高速离心机(型号Eppendorf-5810R)购于eppendorf,电子分析天平(型号:AR1140)购于Ohaus Corp.Brock.NJ.USA,多功能酶标仪(型号Enspire)购于PerkinElmer,超声细胞破碎仪(型号:SONIC RUPTOR 400)购于MONI homogenizer company,震荡裂解仪(型号:FastprepTM-24)购于MP Biomedicals,IVC小鼠饲养笼(型号:ZJ-4)购于苏州市冯氏实验动物设备有限公司。
2.实验方法
2.1除正常对照组外,将小鼠用乙醚轻度麻醉,以100TCID50人冠状病毒229E病毒液滴鼻感染,每只45μl。感染当天开始给药,大、中、小剂量组每次以滴鼻方式给药,给药剂量如表3所示,每天1次,连续4天,正常对照组和模型对照组在同等条件下蒸馏水滴鼻。第5天称重后解剖。取肺称肺重,计算肺指数及肺指数抑制率。结果采用组间比较t检验进行统计学处理。计算公式如下:
肺指数(%)=[肺湿重(g) / 体重(g)] ×100%;
肺指数抑制率(%)=[模型对照组肺重(g)-给药组肺重(g)]/[模型对照组肺重(g)-正常对照组肺重(g)]×100%。
2.2统计方法
采用SPSS 22.0软件进行统计,组间比较采用对照t检验和单因素方差分析,以`x±s表示,采用独立样本t检验或单因素方差分析(ANOVA),然后进行Dunnet检验用于多重比较组间差异,以P<0.05表示统计结果差异具有统计学意义。
3实验结果
表3 对人冠状病毒229E感染小鼠肺炎模型的治疗作用
注:与正常组比较## P<0.01;与模型对照组比较,*P<0.05,** P<0.01
4讨论
采用人冠状病毒229E感染小鼠后,小鼠肺指数明显增高,与正常对照组比较有明显性差异(P<0.01);感染当天开始给予中药挥发油制剂治疗4天后,中药挥发油制剂大、小剂量组肺指数明显降低,与模型对照组比较有明显性差异(P<0.05),肺指数抑制率分别为20.76%、23.46%。
对比例1
为了进一步说明本发明的有益效果,本对比例采用超声-水蒸气蒸馏-减压精馏的方法提取挥发油,茶树挥发油、山腊梅挥发油、月桂叶挥发油、尤加利挥发油、香桃木挥发油、罗纹莎叶挥发油、大西洋雪松挥发油、艾叶挥发油、柠檬挥发油、百里香挥发油和鱼腥草挥发油分别以茶树叶片、山腊梅叶片、月桂叶片、尤加利叶片、香桃木叶片、罗纹莎叶片、大西洋雪松针叶、艾叶、柠檬果皮、百里香全草和鱼腥草全草为原料,分别通过下述方法制得:将各原料粉碎得到碎粒,将碎粒加入相同重量的水中,在40℃下超声处理45min,然后水蒸气蒸馏提取3小时,收集蒸馏液,将蒸馏液进行减压精馏,其中,所述减压蒸馏的条件为:温度为60℃,真空度为60Pa,搅拌速率为400r/min,分离出挥发油。按照实施例1的原料配比和方法制得中药挥发油制剂。
对比例2
为了进一步说明本发明的有益效果,采用与实施例1类似的方法制得中药挥发油制剂,本对比例与实施例1的区别仅在于:本对比例未添加鱼腥草挥发油。
对比例3
为了进一步说明本发明的有益效果,采用与实施例1类似的方法制得中药挥发油制剂,本对比例与实施例1的区别仅在于:本对比例未添加艾叶挥发油和月桂叶挥发油。
(四)各实施例和对比例对各病毒感染小鼠模型的治疗作用
为了进一步说明本发明的有益效果,按照实施例1的试验方法,对上述实施例2~5及对比例1~3所得产品的药效进行测试,测试结果如下表4~6所示。
表4 对副流感病毒(仙台株)感染小鼠肺炎模型的治疗作用
注:与正常组比较## P<0.01;与模型对照组比较,*P<0.05,** P<0.01
表5 对人冠状病毒229E感染小鼠肺炎模型的治疗作用
注:与正常组比较## P<0.01;与模型对照组比较,*P<0.05,** P<0.01
以上对本发明的实施方式作了详细说明,但本发明不限于所描述的实施方式。对于本领域的技术人员而言,在不脱离本发明原理和精神的情况下,对这些实施方式进行多种变化、修改、替换和变型,仍落入本发明的保护范围内。
Claims (3)
1.一种抗病毒中药挥发油制剂,其特征在于,按重量份数计,由如下原料组成:茶树挥发油10~20份、山腊梅挥发油10~20份、百里香挥发油10~20份、月桂叶挥发油5~10份、尤加利挥发油5~10份、柠檬挥发油5~10份、鱼腥草挥发油5~10份、香桃木挥发油5~10份、罗纹莎叶挥发油5~10份、大西洋雪松挥发油5~10份、艾叶挥发油5~10份;
所述茶树挥发油、山腊梅挥发油、月桂叶挥发油、尤加利挥发油、香桃木挥发油、罗纹莎叶挥发油、大西洋雪松挥发油和艾叶挥发油分别以茶树叶片、山腊梅叶片、月桂叶片、尤加利叶片、香桃木叶片、罗纹莎叶片、大西洋雪松针叶和艾叶为原料,分别通过下述方法制得:将对应的叶片原料洗净后平铺在烘房中,放置15~25小时,蒸汽杀青后,气流干燥处理至叶片的水分含量不高于20%,粉碎得到粉末,在0~10℃下冷藏4~10小时,再恢复至25~35℃,再加入0.5~2倍重量的水中,在30~50℃下超声处理2~8小时,然后抽真空蒸馏1~3次,所述抽真空蒸馏的条件为:真空度0.3~0.8Pa,蒸馏温度40~50℃,冷凝温度3~5℃,收集蒸馏液进行超临界二氧化碳萃取即可,所述超临界二氧化碳萃取的条件为:萃取压力为15~18MPa,萃取时间为60~90min,萃取温度为45~55℃,二氧化碳的流速为20~40L/h;
所述百里香挥发油和鱼腥草挥发油分别以百里香全草和鱼腥草全草为原料,分别通过下述方法制得:将新鲜的全草原料洗净后干燥至水分不高于15%,粉碎后加入5~10倍重量的水中,在30~50℃下超声处理1~2小时,然后水蒸气蒸馏提取1~3小时,收集蒸馏液,将蒸馏液进行减压精馏,所述减压精馏的条件为:温度为50~80℃,真空度为50~90Pa,搅拌速率为100~300r/min,分离出挥发油;
所述柠檬挥发油为采用下述方法制得:将新鲜的柠檬果皮粉碎得到柠檬皮碎粒,将柠檬片碎粒加入1~3倍重量的水中,在30~50℃下超声处理30~60min,然后水蒸气蒸馏提取2~4小时,收集蒸馏液,将蒸馏液进行减压精馏,所述减压精馏的条件为:温度为50~70℃,真空度为50~90Pa,搅拌速率为200~500r/min,分离出柠檬挥发油。
2.根据权利要求1所述的抗病毒中药挥发油制剂,其特征在于,按重量份数计,包括如下原料:茶树挥发油15份、山腊梅挥发油15份、百里香挥发油15份、月桂叶挥发油6份、尤加利挥发油6份、柠檬挥发油6份、鱼腥草挥发油7份、香桃木挥发油7.5份、罗纹莎叶挥发油7.5份、大西洋雪松挥发油7.5份、艾叶挥发油7.5份。
3.一种如权利要求1所述的抗病毒中药挥发油制剂在制备抗病毒药物中的应用,所述病毒为人冠状病毒229E或仙台株副流感病毒。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110539335.0A CN113209185B (zh) | 2021-05-18 | 2021-05-18 | 一种广谱抗病毒中药挥发油制剂及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110539335.0A CN113209185B (zh) | 2021-05-18 | 2021-05-18 | 一种广谱抗病毒中药挥发油制剂及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113209185A CN113209185A (zh) | 2021-08-06 |
CN113209185B true CN113209185B (zh) | 2022-12-13 |
Family
ID=77092611
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110539335.0A Active CN113209185B (zh) | 2021-05-18 | 2021-05-18 | 一种广谱抗病毒中药挥发油制剂及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113209185B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115089634A (zh) * | 2022-02-23 | 2022-09-23 | 山西巴盾环境保护技术研究所 | 一种防治新冠肺炎的牛黄/精油组合物及制备方法与应用 |
CN116531547B (zh) * | 2023-03-27 | 2024-07-12 | 广东景兴健康护理实业股份有限公司 | 一种雪松植萃抗敏修复精华液一次性卫生用品护理基材、制备方法及应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102688332A (zh) * | 2011-03-25 | 2012-09-26 | 江苏康缘药业股份有限公司 | 一种治疗感冒的中药组合物及其制备方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111603515B (zh) * | 2020-04-21 | 2022-01-28 | 江苏康缘药业股份有限公司 | 一种中药组合物在制备治疗或预防冠状病毒感染的药物中的应用 |
CN112075459A (zh) * | 2020-07-03 | 2020-12-15 | 张卓 | 抗病毒抑菌呼吸道复方精油和制备方法 |
-
2021
- 2021-05-18 CN CN202110539335.0A patent/CN113209185B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102688332A (zh) * | 2011-03-25 | 2012-09-26 | 江苏康缘药业股份有限公司 | 一种治疗感冒的中药组合物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN113209185A (zh) | 2021-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021218945A1 (zh) | 一种抗菌抗病毒药用组合物及其应用 | |
CN113209185B (zh) | 一种广谱抗病毒中药挥发油制剂及其应用 | |
Kinoshita et al. | Anti-influenza virus effects of elderberry juice and its fractions | |
Wu et al. | Chemical compositions and anti-influenza activities of essential oils from Mosla dianthera | |
JP2007524709A (ja) | Sarsを治療するためのスクテラリア抽出物 | |
CN113209203A (zh) | 一种抗病毒复方精油及其应用 | |
WO2021191886A1 (en) | Compositions comprising terpenes and terpenoids and use thereof for preventing and treating viral-induced infections of the respiratory system | |
Malabadi et al. | Role of botanical essential oils as a therapy for controlling coronavirus (SARS-CoV-2) disease (Covid-19) | |
Huang et al. | Chinese herbal medicine for acute upper respiratory tract infections and reproductive safety: a systematic review | |
CN101966285A (zh) | 一种防治鸡呼吸道疾病的中药、中药气雾剂及其生产方法 | |
KR101118230B1 (ko) | 항-인플루엔자바이러스 조성물 | |
Fasogbon et al. | Positive therapeutic role of selected foods and plant on ailments with a trend towards COVID-19: a review | |
Kalra et al. | Cold and flu: conventional vs. botanical and nutritional therapy | |
Caliskan et al. | Evaluation of botanicals as potential COVID-19 symptoms terminator | |
CN113332400B (zh) | 一种抗病毒中药挥发油组合物及其应用 | |
Prajapati et al. | Prophylaxis and treatment aspect of COVID-19 with the use of Indian traditional plant-based medicine: A hypothetical review | |
Rao et al. | Role of Indian traditional medicine in mitigating novel corona virus effects | |
Tavakoli-Far et al. | Role of Iranian medicinal plants in the prevention of COVID-19 | |
JP5173813B2 (ja) | インフルエンザの予防および処置のための薬剤 | |
CN107320531B (zh) | 一种感冒内病外治的中药活性组分及其生产方法 | |
Armutcu et al. | Herbal Remedies for Respiratory Tract Infections | |
Shrivastava et al. | Potential antiviral efficacy of herbal drugs to fight against COVID-19 | |
Aires et al. | Prophylactic and therapeutic alternatives for respiratory diseases: technological innovations obtained in natural products | |
Mbugi et al. | SARS Cov-2 Structure, biology, immunology and clinical course: Exploring the value of traditional medicine in limiting COVID-19 individual risk and disease outcomes | |
IQBAL et al. | Corona virus-herbal approach for boosting immunity and influencing viral activity. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230602 Address after: 330115 Floors 4-5, Building 1, Xinqizhou Public R&D Center, Traditional Chinese Medicine Innovation City, Ganjiang New District, Nanchang City, Jiangxi Province Patentee after: Jiangxi Guxiang jinyunda Health Industry Co.,Ltd. Address before: 330000 no.1688 Meiling Avenue, Wanli District, Nanchang City, Jiangxi Province Patentee before: JIANGXI University OF TRADITIONAL CHINESE MEDICINE |